Abstract
AIM: Role of Pentoxifylline is compared with placebo in the treatment of Severe Alcoholic Hepatitis. METHODS: Total 20 pts with severe alcoholic hepatitis (Maddrey DF ≥ 32) were included in the study.10 patients received pentoxifylline 400mg TDS for 4wks.And 10 patients received placebo for 4 wks. Baseline characteristics of the two groups were similar. Study was conducted for 4 wks. RESULT: Statistical Analysis was done using student’s t test. The calculated t value found to be 25.01 at 18 df which indicates the difference between Placebo and Pentoxyfylline group is highly significant (P<0.001). Higher baseline Maddrey Discriminant Function was associated with increased mortality. But Pentoxifylline lowers the Maddrey Discriminant Function thus improves survival. CONCLUSION: As compared to Placebo, Pentoxifylline reduce mortality, improved risk-benefit profile and lowers Maddrey Discriminant Function in patients with severe alcoholic hepatitis. Hence it is suggested that pentoxifylline is efficacious in treatment of severe alcoholic hepatitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
